Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus PRECEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus PRECEF.
CEFOBID vs PRECEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
1-2 g IV every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
0.5-1 hour in adults with normal renal function; prolonged to 2-8 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic